GENinCode specializes in risk assessment and prediction of cardiovascular disease , thrombosis and familial hypercholesterolemia . Cardiovascular disease (CVD) is a broad disease classification including coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States. GENinCode provides advanced genomic technology, products and recommendations fully validated by our scientific and clinical team. Our goal is to provide doctors and health care practitioners with advanced health information that combines both traditional clinical measures with a patient’s genetic information to provide a comprehensive risk assessment and clinical recommendation to help decision-making. Our technology helps select the optimal treatment pathway and informs and educates patients to become more aware of their cardiovascular risk helping patient adherence and empowerment to better manage their health. GENinCode technology and advanced genomic products provide information that helps patients and healthcare practitioners to assess and predict the onset of cardiovascular disease, thrombosis, and the diagnosis of Familial Hypercholesterolemia. Our online reporting system SITAB® helps inform doctors of their patients’ health risk enabling patient behavioral and lifestyle changes alongside delivering the most effective therapies and treatment pathways.
| Website | https://www.genincode.com/ |
| Employees | 47 (37 on RocketReach) |
| Founded | 2018 |
| Address | Robert Robinson Avenue, John Eccles House, Oxford, England OX4 4GP, GB |
| Phone | +44 7800 903435 |
| Industry | Biotechnology Research |
| Competitors | Guardant Health, GRAIL, Myriad Genetics, Foundation Medicine, GeneDx, Invitae, Fulgent Genetics, 23andMe, Genomic Health, Color +34 more (view full list) |
Looking for a particular GENinCode Predictive Genetics employee's phone or email?
Matthew Walls is the CEO of GENinCode Predictive Genetics.
37 people are employed at GENinCode Predictive Genetics.
GENinCode Predictive Genetics is based in Oxford, England.